Harita S, Shimokawa Y, Mibu Y, Ishida M, Hayashi H
Immunology. 1984 Feb;51(2):295-303.
As recently reported, one lymphocyte chemotactic factor (beta-LCF, mol. wt. about 27,000) released from activated guinea-pig lymphocytes appeared to be identical to one of the LCFs (LCF-d) isolated from extract of purified protein derivative (PPD)-induced delayed-type hypersensitivity skin reaction sites in guinea-pigs with respect to antigenicity and chemotactic effect for T cells. However, the mol. wt. of LCF-d (about 300,000) was clearly distinct from beta-LCF. The experiments were undertaken to clarify the problem. beta-LCF appeared to be bound to some protein of normal guinea-pig serum (GPS) because the chemotactic activity was revealed in the fraction corresponding to that of LCF-d when the mixtures of beta-LCF with GPS were applied to a Sephadex G-200 column. Additionally, binding experiments using fluorescein isothiocyanate (FITC)-labelled beta-LCF were performed; fluorescence was only detected in the chemotactic fraction. It was thus assumed that the lymphokine (beta-LCF) would be released from activated lymphocytes around the inflammatory tissue, then bound with serum protein exuded in the site and function as LCF-d. The possibility was supported by the evidence that beta-LCF like-chemotactic substance (mol. wt. about 27,000) was dissociated from LCF-d under acid conditions. The factor dissociated from LCF-d was also bound with GPS protein under neutral conditions and converted to high molecular substance resembling LCF-d physiochemically. Furthermore, the chemotactic activity of LCF-d was almost completely absorbed by antibody against GPS. It is thus considered that the chemotactic activity of LCF-d may be attributed to beta-LCF released from activated lymphocytes and that some serum protein which binds beta-LCF may function as a carrier protein in the DTH sites.
最近有报道称,从活化的豚鼠淋巴细胞释放的一种淋巴细胞趋化因子(β-LCF,分子量约27,000),就其对T细胞的抗原性和趋化作用而言,似乎与从纯化蛋白衍生物(PPD)诱导的豚鼠迟发型超敏皮肤反应部位提取物中分离出的一种LCF(LCF-d)相同。然而,LCF-d的分子量(约300,000)与β-LCF明显不同。进行这些实验是为了阐明这个问题。β-LCF似乎与正常豚鼠血清(GPS)的某些蛋白质结合,因为当β-LCF与GPS的混合物应用于Sephadex G-200柱时,趋化活性在与LCF-d相对应的级分中显现出来。此外,还进行了使用异硫氰酸荧光素(FITC)标记的β-LCF的结合实验;仅在趋化级分中检测到荧光。因此推测,淋巴因子(β-LCF)将从炎症组织周围的活化淋巴细胞中释放出来,然后与渗出到该部位的血清蛋白结合,并作为LCF-d发挥作用。β-LCF样趋化物质(分子量约27,000)在酸性条件下从LCF-d中解离出来的证据支持了这种可能性。从LCF-d解离出来的因子在中性条件下也与GPS蛋白结合,并在物理化学性质上转化为类似于LCF-d的高分子物质。此外,LCF-d的趋化活性几乎完全被抗GPS抗体吸收。因此可以认为,LCF-d的趋化活性可能归因于活化淋巴细胞释放的β-LCF,并且一些结合β-LCF的血清蛋白可能在迟发型超敏反应部位起载体蛋白的作用。